A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia

British Journal of Haematology

Volumn 167, Issue 5, 2014, Pages 618-625

  Bradstock, Kenneth F ^a   Link, Emma ^b   Collins, Marnie ^b   Di Iulio, Juliana ^b   Lewis, Ian D ^c   Schwarer, Anthony ^d   Enno, Arno ^e   Marlton, Paula ^f   Hahn, Uwe ^g   Szer, Jeff ^h   Cull, Gavin ⁱ   Seymour, John F ^b,j  

^a WESTMEAD HOSPITAL   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d BOX HILL HOSPITAL   (Australia)

^e NEWCASTLE MATER HOSPITAL   (Australia)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g QUEEN ELIZABETH HOSPITAL   (Australia)

^h ROYAL MELBOURNE HOSPITAL   (Australia)

ⁱ SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^j UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

Acute myeloid leukaemia; Chemotherapy; Keratinocyte growth factor; Mucositis; Palifermin

Indexed keywords

CYTARABINE; ETOPOSIDE; IDARUBICIN; KERATINOCYTE GROWTH FACTOR; PALIFERMIN; PEGFILGRASTIM; PLACEBO; ANTINEOPLASTIC AGENT;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGRESSION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; ORAL MUCOSITIS; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN EXFOLIATION; VOMITING; CHEMICALLY INDUCED; CLINICAL TRIAL; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; STOMATITIS;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; ETOPOSIDE; FIBROBLAST GROWTH FACTOR 7; HUMANS; IDARUBICIN; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; STOMATITIS;

EID: 84925221806     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13086     Document Type: Article

References (32)

1. 2 or lower with use of palifermin for cytoprotection: results of a phase I trial. Biology of Blood and Marrow Transplantation, 18, 1455-1461.
2. Berman, E., Heller, G., Santorsa, J., McKenzie, S., Gee, T., Kempin, S., Gulati, S., Andreeff, M., Kolitz, J. & Gabrilove, J. (1991) Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood, 77, 1666-1674.
3. Bishop, J.F., Lowenthal, R.M., Joshua, D., Matthews, J.P., Todd, D., Cobcroft, R., Whiteside, M.G., Kronenberg, H., Ma, D. & Dodds, A. (1990) Australian Leukaemia Study Group: etoposide in acute nonlymphocytic leukemia. Blood, 75, 27-32.
4. Bishop, J., Matthews, J., Young, G., Szer, J., Gillett, A., Joshua, D., Bradstock, K., Enno, A., Wolf, M.M. & Fox, R. (1996) A randomized trial of high-dose cytarabine in induction in acute myeloid leukemia. Blood, 87, 1710-1717.
5. Bradstock, K.F., Matthews, J.P., Young, G.A.R., Lowenthal, R.M., Baxter, H., Arthur, C., Brighton, T., Cannell, P., Dunlop, L., Durrant, S., Enno, A., Eliadis, P., Gill, D., Gillett, A., Gottlieb, D., Januszewicz, H., Joshua, D., Leahy, M., Schwarer, A. & Taylor, K. (2001) Effects of glycosylated granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia. Leukemia, 15, 1331-1338.
6. Bradstock, K.F., Matthews, J.P., Lowenthal, R.M., Baxter, H., Catalano, J., Brighton, T., Gill, D., Elliadis, P., Joshua, D., Cannell, P., Schwarer, A.P., Durrant, S., Gillett, A., Koutts, J., Taylor, K., Bashford, J., Arhur, C., Enno, A., Dunlop, L., Szer, J., Leahy, M., Juneja, S. & Young, G.A.R. (2005) A randomized trial of high versus conventional dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood, 105, 481-487.
7. Buchner, T., Hiddemann, W., Wormann, B., Loeffler, H., Gassman, W., Hafferlach, T., Fonatsch, C., Haase, D., Schoch, C., Hossfeld, D., Lengfelder, D., Aul, C., Heyll, A., Maschmeyer, G., Ludwig, W.D., Sauerland, M.C. & Heinecke, A. (1999) Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood, 93, 4116-4124.
8. Dillman, R., Davis, R., Green, M., Weiss, R.B., Gottlieb, A.J., Caplan, S., Kopel, S., Preisler, H., McIntyre, O.R. & Schiffer, C. (1991) A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III study of Cancer and Leukemia Group B. Blood, 78, 2520-2526.
9. Elling, L.S., Shih, Y.C., Stiff, P.J., Bensiger, W., Cantor, S.B., Cooksley, C., Spielberger, R. & Emmanoulides, C. (2007) Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem cell transplant: analysis of phase 3 trial results. Biology of Blood and Marrow Transplantation, 13, 806-813.
10. Estey, E.H., Thal, P.F., Cortes, J.E., Giles, F.J., O'Brien, S., Pierce, S.A., Wang, X., Kantarjian, H.M. & Beran, M. (2001) Comparison of idarubicin- ara-C-, fludarabine - ara-C-, and topotecan -ara-C-based regimens in the treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood, 98, 3575-3583.
11. Farrell, C.L., Bready, J.V., Rex, K.L., Chen, J.N., DiPalma, C.R., Whitcomb, L., Yin, S., Hill, D.C., Wiemann, B., Starnes, C.O., Havill, A.M., Lu, Z.N., Aukerman, S.L., Pierce, G.F., Thomason, A., Potten, C.S., Ulich, T.R. & Lacey, D.L. (1998) Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Research, 58, 933-939.
12. Fernandez, H.F., Sun, Z., Yao, X., Litzrow, M.R., Luger, S.M., Paietta, E.M., Racevskis, J., Dewald, G.W., Ketterling, R.P., Bennett, J.M., Rowe, J.M., Lazarus, H.M. & Tallman, M.S. (2009) Anthracycline dose intensification in acute myeloid leukemia. New England Journal of Medicine, 361, 1249-1259.
13. Goldberg, J.D., Zheng, J., Castro-Malaspina, H., Jakubowski, A.A., Heller, G., van der Brink, M.R. & Perales, M.A. (2013) Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based hematopoietic stem cell transplants. Bone Marrow Transplantation, 48, 99-104.
14. Hensley, M.L., Hagerty, K.L., Kewelramani, T., Green, D.M., Meropol, M., Wasserman, T.H., Cohen, G.I., Emami, B., Gradishar, W.J., Mitchell, R.B., Thigpen, J.T., Trotti, A. III, von Hoff, D. & Schuchter, L.M. (2009) ASCO 2008 Clinical Practice guidelines: use of chemotherapy and radiation therapy protectants. Journal of Clinical Oncology, 27, 127-145.
15. Iland, H., Bradstock, K.F., Seymour, J., Hertzberg, M.S., Grigg, A., Taylor, K., Catalano, J., Cannell, P., Horvath, N., Deveridge, S., Browett, P., Brighton, T., Chong, L., Springall, F., Ayling, J., Catalano, A., Supple, S., Collins, M., Di Iulio, J. & Reynolds, J. (2012a) Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Hematologica, 97, 227-234.
16. Iland, H.J., Bradstock, K.F., Supple, S., Catalano, A., Collins, M., Hertzberg, M.S., Browett, P., Grigg, A., Firkin, F., Hugman, A., Reynolds, J., Di Iulio, J., Tiley, C., Taylor, K., Filshie, R., Seldon, M., Taper, J., Szer, J., Moore, J., Bashford, J. & Seymour, J.F. (2012b) All-trans-retinoic acid, idarubicin, and intravenous arsenic trioxide as initial therapy in acute promyelocytic leukemia: the Australasian Leukaemia and Lymphoma Group APML4 trial. Blood, 120, 1570-1580.
17. van der Jagt, A., Muirhead, J., Seymour, J.F., Bradstock, K.F., Paul, E. & Wei, A. (2012) Risk factors for early death after high-dose cytosine arabinoside (HiDAC)-based chemotherapy for adult AML. Leukemia, 26, 362-365.
18. Johansson, J.E., Hasseus, B., Johansson, P., Eklof, C., Ohman, D. & Stockelberg, D. (2009) Gut protection by palifermin during autologous hematopoietic stem cell transplantation. Bone Marrow Transplantation, 43, 808-811.
19. Kobbe, G., Bruns, I., Schroeder, T., Czibere, A., Warnecke, J., Hieronimus, N., Safaian, N., Kondakci, M., Saure, C., Germing, U., Haas, R. & Fenk, R. (2010) A 3 day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem cell transplantation in patients with multiple myeloma. Annals of Oncology, 21, 1898-1904.
20. Lowenberg, B., Ossenkoppele, G.J., van Putten, W., Schouten, H.C., Graux, C., Ferrant, A., Sonneveld, P., Maertens, J., Jongen-Lavrencic, M., von Lilienfeld-Toal, M., Biermond, B.J., Vellenga, E., van Marwijk-Kooy, M., Verdonck, L.F., Beck, J., Doehner, H., Gratwohl, A., Pabst, T. & Verhoef, G. (2009) High dose daunorubicin in older patients with acute myeloid leukemia. New England Journal of Medicine, 361, 1235-1248.
21. Mandelli, F., Petti, M., Ardia, A., Di Pietro, N., Di Raimondi, F., Ganzina, F., Falconi, E., Geraci, E., Ladogana, S., Latagliata, R., Malleo, C., Nobile, F., Petti, N., Rotoli, B., Specchia, G., Tabilio, A. & Resegotti, L. (1991) A randomized clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. European Journal of Cancer, 27, 750-755.
22. Mayer, R., Davis, R., Schiffer, C., Berg, D.T., Powell, B.L., Schulman, P., Omura, G.A., Moore, J.O., McIntyre, O.R. & Frei, E. III (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. New England Journal of Medicine, 331, 896-903.
23. Miller, A.B., Hoogstraten, B., Staquet, M. & Winkler, A. (1981) Reporting results of cancer treatment. Cancer, 47, 207-214.
24. Rubin, J.S., Osada, H., Finch, P.W., Taylor, W.G., Rudikoff, S. & Aaronson, S.A. (1989) Purification and characterization of a newly identified growth factor specific for epithelial cells. Proceedings of National Academy of Science USA, 86, 802-806.
25. Spielberger, R., Stiff, P., Bensiger, W., Gentile, T., Weissdorf, D., Kewalramani, T., Shea, T., Yanovich, S., Hansen, K., Noga, S., McCarty, J., LeMaistre, F., Sung, E.C., Blazar, B.R., Elhardt, D., Chen, M.G. & Emmanouilides, C. (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. New England Journal of Medicine, 351, 2590-2598.
26. Stiff, P.J., Emmanouilides, C., Bensinger, W.I., Gentile, T., Blazar, B., Shea, T., Lu, J., Islitt, J., Cesano, A. & Spielberger, R. (2006) Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. Journal of Clinical Oncology, 24, 5186-5193.
27. Tsirigotis, P., Triantafyllou, K., Girkas, K., Giannopoulou, V., Iaonnidou, E., Chondropoulos, S., Kalli, T., Papxoinis, G., Pappa, V., Papageorgiou, E., Economopoulos, T., Ladas, S.D. & Dervenoulas, J. (2008) Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study. Bone Marrow Transplantation, 42, 337-343.
28. Vardiman, J.W., Harris, J.W. & Brunning, R.D. (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 100, 2292-2302.
29. Vogler, W., Velez-Garcia, E., Weiner, R., Flaum, M.A., Bartolucci, A.A., Omura, G.A., Gerber, M.C. & Banks, P.L. (1992) A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. Journal of Clinical Oncology, 10, 1103-1111.
30. Weick, J., Kopecky, K., Appelbaum, F., Head, D.R., Kingsbury, L.L., Balcerzak, S.P., Bickers, J.N., Hynes, H.E., Welborn, J., Simon, S. & Grever, M. (1996) A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group Study. Blood, 88, 2841-2851.
31. Wiernik, P., Banks, P., Case, D. Jr, Arlin, Z.A., Periman, P.O., Todd, M.B., Ritch, P.S., Enck, R. & Weitburg, A. (1992) Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood, 79, 313-319.
32. Yates, J., Glidewell, O., Wiernik, P., Cooper, M.R., Steinberg, D., Dosik, H., Levy, R., Hoagland, C., Henry, P., Gottlieb, A., Cornell, C., Berenberg, J., Hutchison, J.L., Raich, P., Nissen, N., Ellison, R.R., Frelick, R., James, G.W., Falkson, G., Silver, R.T., Haurani, F., Green, M., Henderson, E., Leone, L. & Holland, J.F. (1982) Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood, 60, 454-462.